Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Peer Review reports

Original Submission
23 Jan 2017	Submitted	Original manuscript
6 Aug 2017	Author responded	Author comments - Arthur Braat
Resubmission - Version 2
6 Aug 2017	Submitted	Manuscript version 2
17 Aug 2017	Reviewed	Reviewer Report - Douglas Coldwell
29 Oct 2017	Reviewed	Reviewer Report - Steven Colquhoun
28 Nov 2017	Reviewed	Reviewer Report - Julius Chapiro
22 Jan 2018	Author responded	Author comments - Arthur Braat
Resubmission - Version 3
22 Jan 2018	Submitted	Manuscript version 3
12 Mar 2018	Reviewed	Reviewer Report - Julius Chapiro
15 May 2018	Author responded	Author comments - Arthur Braat
Resubmission - Version 4
15 May 2018	Submitted	Manuscript version 4
4 Jun 2018	Author responded	Author comments - Arthur Braat
Resubmission - Version 5
4 Jun 2018	Submitted	Manuscript version 5
Publishing
5 Jun 2018	Editorially accepted
15 Jun 2018	Article published	10.1186/s12876-018-0817-8

Back to article page